GSK plc announced that a two-dose schedule for its HPV vaccine Cervarix [Human Papillomavirus bivalent (types 16, 18) Vaccine, Recombinant)] has been approved by China's NMPA for girls aged 9 to 14. With this approval, Cervarix is the first imported two-dose HPV vaccine for this age group in mainland China. The NMPA authorisation of the two-dose regimen adds China to two-dose approvals in approximately 100 countries, including the European Union, Asia, Africa, and Latin America2-7. The three-dose schedule remains on the label for girls and women aged 15-45 years in China.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,651 GBX | -0.02% | +3.84% | +13.85% |
10:51am | GSK: FDA priority review for endometrial cancer | CF |
10:14am | GSK's Jemperli with chemotherapy accepted for priority review by FDA | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.81% | 83.92B | |
+27.92% | 672B | |
+27.07% | 570B | |
-4.59% | 360B | |
+16.38% | 321B | |
+9.39% | 300B | |
+7.43% | 217B | |
+5.87% | 199B | |
-8.51% | 204B | |
-8.58% | 149B |
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- NMPA Approves Two-Dose Schedule for HPV Vaccine Cervarix of GSK plc